Hunan Er Kang Pharmaceutical Total Liabilities
Hunan Er Kang Pharmaceutical total liabilities. Based on the latest financial reports, Hunan Er Kang Pharmaceutical (300267) has total liabilities worth CN¥634.44 Million CNY (≈ $92.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Hunan Er Kang Pharmaceutical to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hunan Er Kang Pharmaceutical (2008–2024)
Total liabilities of Hunan Er Kang Pharmaceutical from 2008 to 2024. This chart illustrates how Hunan Er Kang Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data.
Hunan Er Kang Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Hunan Er Kang Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Synsam AB
ST:SYNSAM
|
Sweden | Skr5.83 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥278.25 Million |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥85.18 Million |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
China | CN¥1.75 Billion |
|
Shandong Intco Recycling Resources Co Ltd
SHG:688087
|
China | CN¥4.91 Billion |
|
Ficont Industry (Beijing) Co. Ltd.
SHG:605305
|
China | CN¥664.38 Million |
|
Gr. Sarantis S.A.
AT:SAR
|
Greece | €232.08 Million |
|
UNITIL Corporation
NYSE:UTL
|
USA | $1.35 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Hunan Er Kang Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hunan Er Kang Pharmaceutical assets under control.
Liquidity & Leverage Metrics
Hunan Er Kang Pharmaceutical Total Liabilities Ratios Explained
Hunan Er Kang Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Er Kang Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Er Kang Pharmaceutical (2008–2024)
The table below shows the annual total liabilities of Hunan Er Kang Pharmaceutical from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥797.54 Million ≈ $116.71 Million |
+19.20% |
| 2023-12-31 | CN¥669.05 Million ≈ $97.90 Million |
-16.84% |
| 2022-12-31 | CN¥804.57 Million ≈ $117.73 Million |
+44.12% |
| 2021-12-31 | CN¥558.28 Million ≈ $81.69 Million |
-25.88% |
| 2020-12-31 | CN¥753.22 Million ≈ $110.22 Million |
+114.77% |
| 2019-12-31 | CN¥350.72 Million ≈ $51.32 Million |
-14.33% |
| 2018-12-31 | CN¥409.39 Million ≈ $59.91 Million |
+32.76% |
| 2017-12-31 | CN¥308.37 Million ≈ $45.12 Million |
-24.59% |
| 2016-12-31 | CN¥408.94 Million ≈ $59.84 Million |
-24.84% |
| 2015-12-31 | CN¥544.10 Million ≈ $79.62 Million |
+0.27% |
| 2014-12-31 | CN¥542.64 Million ≈ $79.41 Million |
+380.19% |
| 2013-12-31 | CN¥113.01 Million ≈ $16.54 Million |
+54.13% |
| 2012-12-31 | CN¥73.32 Million ≈ $10.73 Million |
+11.25% |
| 2011-12-31 | CN¥65.90 Million ≈ $9.64 Million |
-44.69% |
| 2010-12-31 | CN¥119.15 Million ≈ $17.44 Million |
+57.36% |
| 2009-12-31 | CN¥75.72 Million ≈ $11.08 Million |
+27.54% |
| 2008-12-31 | CN¥59.37 Million ≈ $8.69 Million |
-- |
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more